AFP and hepatocellular carcinoma: Among early HCC (stages 0-A), we found that 28.5% (10/35) of patients had elevated AFP concentration, while 62.9% (22/35) and 80.0% (28/35) of patients had elevated levels of MIR4435-2HG and lnc-POLD3-2, respectively (Figure S5).